CompletedNCT03596034
Official study titleA Study to Characterize Puff Topography With Use of a JUUL 5% Electronic Nicotine Delivery Systems (ENDS) in Adult Smokers
This study has finished and is no longer accepting participants.
Multiple locations, including CharlotteAddictionInterventional studyAges 21–65
- Countries
- United States
- Sponsor
- Juul Labs, Inc.
CompletedNCT02431702
Official study titleA Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–35
- Countries
- United States, Brazil, Mexico
- Sponsor
- Janssen Scientific Affairs, LLC
CompletedNCT00210717
About this title
A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia
Read the official source — NCT00210717Official study titleA Randomized, Double-Blind, Parallel Group, Comparative Study of Flexibly Dosed Paliperidone Palmitate (25, 50, 75, or 100 mg eq.) Administered Every 4 Weeks and Flexibly Dosed RISPERDAL CONSTA (25, 37.5, or 50 mg) Administered Every 2 Weeks in Subjects With Schizophrenia
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18+
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT00645372
About this title
A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients
Read the official source — NCT00645372What is this study about?Researchers compared Ziprasidone and Risperidone to find out how the approaches affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including BeijingSchizophreniaMedication studyAges 18–65
- Countries
- China
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
CompletedNCT03321526
What is this study about?This study evaluated the safety and effectiveness of JNJ-42847922 for people with depression.
This study has finished and is no longer accepting participants.
Multiple locations, including PhoenixDepressionMedication studyAges 18–70
- Countries
- United States
- Sponsor
- Janssen Research & Development, LLC
CompletedNCT01654601
Official study titleClinical Trials to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg After a Multi-dose Oral Administration in Schizophrenia Patients
This study has finished and is no longer accepting participants.
Multiple locations, including ChoongjuSchizophreniaMedication studyAges 20–60
- Countries
- South Korea
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
CompletedNCT00392743
About this title
A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers and in Schizophrenic Patients
Read the official source — NCT00392743Official study titleAn Open-label, Cross-over Study, to Compare the PET and SPECT Measurement of Antipsychotic-induced D2 Receptor Occupancy, in a Group of Healthy Volunteers and in Another Group of Patients With Schizophrenia and Other Psychotic Disorders
This study has finished and is no longer accepting participants.
Multiple locations, including BarcelonaSchizophreniaObservational studyAges 18+
- Countries
- Spain
- Sponsor
- GlaxoSmithKline
WithdrawnNCT02418702
Official study titleA Randomized Controlled Trial to Decrease Suicidal Thinking Using Ketamine
This study was withdrawn before enrollment.
In San DiegoDepressionMedication studyAges 18–65
- Countries
- United States
- Sponsor
- United States Naval Medical Center, San Diego
CompletedNCT04463108
Official study titleA Description of Routine Treatment Pathways in a Cohort of Patients With Major Depression and "Active Suicidal Ideation With Intent" in Italy: the Arianna Observational Study.
This study has finished and is no longer accepting participants.
Multiple locations, including BresciaDepression, SuicidalityObservational studyAges 18–74
- Countries
- Italy
- Sponsor
- Janssen-Cilag S.p.A.
CompletedNCT00518232
About this title
A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder
Read the official source — NCT00518232Official study titleThe Effective and Tolerable Titration Scheme and Dosage in Children With Attention-deficit Hyperactivity Disorder Treated With OROS-Methylphenidate
This study has finished and is no longer accepting participants.
Location not clearly listedADHDMedication studyAges 6–19
- Countries
- Sponsor
- Johnson & Johnson Taiwan Ltd
CompletedNCT03751488
Official study titleA Randomized, Single-Dose, Open-Label, Parallel-Group Study to Determine the Relative Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients
This study has finished and is no longer accepting participants.
Multiple locations, including Garden GroveSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Luye Pharma Group Ltd.
CompletedNCT00212797
About this title
A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)
Read the official source — NCT00212797What is this study about?This study evaluated the safety and effectiveness of Org 34517 for people with depression.
This study has finished and is no longer accepting participants.
Location not clearly listedDepression, SchizophreniaMedication studyAges 18–70
- Countries
- Sponsor
- Merck Sharp & Dohme LLC